abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Story

13 Jan 2015

Médecins Sans Frontières raises concerns over Gilead Sciences' anti-diversion programme for Hepatitis C drug

Médecins Sans Frontières released a briefing paper in January 2015 highlighting "serious ethical concerns" over Gilead Sciences' anti-diversion programme for a hepatitis C (HCV) drug.  These concerns relate to the right to health and privacy, and access to medicines.

Business & Human Rights Resource Centre invited Gilead Sciences to respond to the briefing.  The full briefing and the company's response are provided below.

Company Responses

Gilead Sciences View Response

Timeline